Technical Articles
11 Apr 2025
Crystal’s Perspective: Polymorph Patent Landscape of 28 FDA-Approved Small Molecule Drugs in 2024
11 Apr 2025
en
Chief Science Officer & Head of Bioanalysis and Biomarkers Lab
A world-renowned molecular pharmacologist with intimate knowledge of the drug development and product regulatory submission process. She is recognized as an industry key opinion leader in biomarker discovery and bioanalytical assay development.
Before joining Crystal Bio Solutions, Dr. Liang served as Amador's Chief Technology Officer and President of Bioanalysis and Biometrics. Before joining Amador, Dr. Liang held several positions of increasing responsibility at Berlex Biosciences, Abgenix, and Amgen. Later, she joined MedImmune, a wholly owned subsidiary of AstraZeneca, where she became the Executive Director and Global Head of Integrated Bioanalysis.
Dr. Liang earned a Bachelor of Science in Pharmacy from Beijing University Medical School, a PhD in Pharmacology from the University of North Carolina, and a Postdoctoral Fellow in Pharmacology from the University of Virginia. She has also written and published more than 70 scientific articles and is listed as an inventor on more than 15 patents.
